UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026 Trial costs ...
59m
EQT Corporation: EQT Reports Fourth Quarter and Full Year 2025 Results and Provides 2026 Guidance
EQT Corporation (NYSE: EQT) today announced financial and operational results for the fourth quarter and full year 2025 as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results